Eszopiclone for persistent negative symptoms in schizophrenia – An unintended N-of-1 study
In this report we highlight the potential utility of eszopiclone in treating persistent negative symptoms in a patient with chronic schizophrenia. (Source: Schizophrenia Research)
Source: Schizophrenia Research - June 21, 2017 Category: Psychiatry Authors: Urvakhsh Meherwan Mehta, Vinutha Ravishankar, Jagadisha Thirthalli Source Type: research
GABAA receptor positive allosteric modulators modify the abuse-related behavioral and neurochemical effects of methamphetamine in rhesus monkeys.
Abstract
GABAA receptor positive allosteric modulators (GABAA receptor modulators) are commonly used for the treatment of insomnia. Nevertheless, the effects of these compounds on psychostimulant-induced sleep impairment are poorly understood. Because GABAA receptor modulators have been shown to decrease the abuse-related effects of psychostimulants, the aim of the present study was to evaluate the effects of temazepam (0.3, 1.0 or 3.0 mg/kg) and eszopiclone (0.3, 1.0 or 3.0 mg/kg), two GABAA receptor modulators, on the behavioral neuropharmacology of methamphetamine in adult rhesus macaques (n = 5). S...
Source: Neuropharmacology - May 8, 2017 Category: Drugs & Pharmacology Authors: Berro LF, Andersen ML, Tufik S, Howell LL Tags: Neuropharmacology Source Type: research
Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem ‐containing medications
ConclusionThe DSCs related to zolpidem‐containing products shifted prescribing toward the lower‐dose formulations, consistent with the recommendations in the DSCs. Copyright © 2017 John Wiley & Sons, Ltd. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - April 27, 2017 Category: Drugs & Pharmacology Authors: Aaron S. Kesselheim, Macarius Donneyong, Gerald J. Dal Pan, Esther H. Zhou, Jerry Avorn, Sebastian Schneeweiss, John D. Seeger Tags: Original Report Source Type: research
The dual orexin receptor antagonist, DORA ‐22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine
This article is protected by copyright. All rights reserved. (Source: Journal of Neurochemistry)
Source: Journal of Neurochemistry - April 26, 2017 Category: Neuroscience Authors: Lihang (Leon) Yao, Andres Ramirez, Anthony J. Roecker, Steven Fox, Jason Uslaner, Sean M. Smith, Robert Hodgson, Paul J. Coleman, John J. Renger, Christopher J. Winrow, Anthony L. Gotter Tags: Original Article Source Type: research
Response to a combination of oxygen and a hypnotic as treatment for obstructive sleep apnoea is predicted by a patient's therapeutic CPAP requirement
ConclusionTherapeutic CPAP requirement, as a surrogate measure of pharyngeal collapsibility, predicts the response to non‐anatomical therapy (oxygen and eszopiclone) for OSA. (Source: Respirology)
Source: Respirology - April 14, 2017 Category: Respiratory Medicine Authors: Shane A. Landry, Simon A. Joosten, Scott A. Sands, David P. White, Atul Malhotra, Andrew Wellman, Garun S. Hamilton, Bradley A. Edwards Tags: Original Article Source Type: research
